These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15855890)

  • 1. Molecularly targeted therapies for breast cancer.
    Hobday TJ; Perez EA
    Cancer Control; 2005 Apr; 12(2):73-81. PubMed ID: 15855890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecularly targeted therapeutics for breast cancer.
    Hussain SA; Palmer DH; Spooner D; Rea DW
    BioDrugs; 2007; 21(4):215-24. PubMed ID: 17628119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents in development for breast cancer.
    Gao XP; Liu F
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):68-74. PubMed ID: 17218855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in the treatment of colorectal cancers.
    Alekshun T; Garrett C
    Cancer Control; 2005 Apr; 12(2):105-10. PubMed ID: 15855893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the impact of conventional systemic therapies on breast cancer.
    Howell A; Wardley AM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S9-S16. PubMed ID: 16113103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.
    Pruthi S; Boughey JC; Brandt KR; Degnim AC; Dy GK; Goetz MP; Perez EA; Reynolds CA; Schomberg PJ; Ingle JN
    Mayo Clin Proc; 2007 Sep; 82(9):1131-40. PubMed ID: 17803883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 10. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors in breast cancer: an overview.
    Altundag K; Ibrahim NK
    Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):5-16. PubMed ID: 19364051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.
    Petrelli F; Cabiddu M; Cazzaniga ME; Cremonesi M; Barni S
    Oncologist; 2008 Apr; 13(4):373-81. PubMed ID: 18448551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapies in breast cancer: where are we now?
    Widakowich C; de Azambuja E; Gil T; Cardoso F; Dinh P; Awada A; Piccart-Gebhart M
    Int J Biochem Cell Biol; 2007; 39(7-8):1375-87. PubMed ID: 17543572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family.
    Sartor CI
    Semin Oncol; 2000 Dec; 27(6 Suppl 11):15-20; discussion 92-100. PubMed ID: 11236022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.